Smartphone App Checks Liver Scarring in People with Diabetes
Tests a smartphone app that estimates liver scarring in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Liver Fibrosis Assessment in Diabetic Patients
Key facts
- Where
- Taipei, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Source: NCT06694974, who can take part
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT06694974
- Record updated
- 22 November 2024
- Original description
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the identification, and management of liver fibrosis. This is to establish a patient-centered clinical pathway to identify patients with advanced fibrosis in type 2 diabetes patients. The investigators plan to conduct this randomized controlled trial of two groups: FIB-4 APP group and the standard care group. The primary end point is the referral rate of patients with advanced fibrosis (FIB-4 ≥ 2.67).Read full original descriptionShow less
A Randomized Controlled Trial for Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the identification, and management of liver fibrosis. This is to establish a patient-centered clinical pathway to identify patients with advanced fibrosis in type 2 diabetes patients. The investigators plan to conduct this randomized controlled trial of two groups: FIB-4 APP group and the standard care group. The primary end point is the referral rate of patients with advanced fibrosis (FIB-4 ≥ 2.67).
Inclusion: Type 2 diabetes patients, regular follow-up in OPD every 3 months; Age 35-65 (Because FIB-4 is not accurate in people with age <35 or > 65).
Exclusion: Patients are regularly follow the investigators at the liver clinic for liver disease; Active malignancy; Hematology disease with thrombocytopenia; Pregnant patients with type 2 diabetes.